与此同时,该公司在周二收盘后表示,Idera 不再招募患者进入 tilsotolimod 与 BMS的 Yervoy 和 ...查看全文
$井寺制药(IDRA)$ 内部交易: 2016-05-13,Director,GERAGHTY JAMES A ,买入,10000普通股, $1.34
$井寺制药(IDRA)$ 10-Q - Quarterly report [Sections 13 or 15(d)] Filed: 2016-05-09 AccNo: 0001193125-16-583789 Size: 2 MB 网页链接
$井寺制药(IDRA)$ 美东时间 2016-05-09 17:00 Q1 2016 Idera Pharmaceuticals Inc Earnings Call 网页链接
$井寺制药(IDRA)$ EFFECT - Notice of Effectiveness Filed: 2016-04-26 AccNo: 9999999995-16-004329 Size: 1 KB 网页链接
$井寺制药(IDRA)$ DEF 14A - Other definitive proxy statements Filed: 2016-04-25 AccNo: 0001558370-16-004806 Size: 1 MB 网页链接
$井寺制药(IDRA)$ 美东时间 2016-04-12 15:40 Idera Pharmaceuticals Inc at Needham Healthcare Conference 网页链接
$井寺制药(IDRA)$ 美东时间 2016-04-12 15:40 Idera Pharmaceuticals Inc at Needham Healthcare Conference 网页链接
$井寺制药(IDRA)$ 内部交易: 2016-03-15,总裁 & CEO,MILANO VINCENT ,买入,40000普通股, $1.97
$井寺制药(IDRA)$ S-8 - Securities to be offered to employees in employee benefit plans Filed: 2016-03-11 AccNo: 0001193125-16-500435 Size: 102 KB 网页链接
$井寺制药(IDRA)$ S-3 - Registration statement under Securities Act of 1933 Filed: 2016-03-11 AccNo: 0001193125-16-501669 Size: 151 KB 网页链接